Portage Announces Additional Consultants To Expedite Its PPL-003 Development Programs

PPL-003 uses a new proprietary cell permeable peptide platform technology derived from human genes to deliver its anti-inflammatory cargo into the eye. , PhD, who is a pharmaceutical technologist with experience in biopharmaceutical products as well as small organics and has been responsible for product development in companies including Amylin Pharmaceuticals, Guilford Pharmaceuticals, and Mannkind Pharmaceuticals.

http://ift.tt/ZOYftX